



## **Enanta Pharmaceuticals to Present at the 32nd Annual J.P. Morgan Healthcare Conference**

January 6, 2014

[Download this Press Release](#)

### **Presentation to be Webcast on January 14, 2014 at 11:00 A.M. PT**

WATERTOWN, Mass.--(BUSINESS WIRE)--Jan. 6, 2014-- Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will make a presentation regarding the company on January 14, 2014, at 11:00 A.M. PT during the 32<sup>nd</sup> Annual J.P. Morgan Healthcare Conference in San Francisco. A question and answer session with investors will follow the presentation.

The presentation and the question and answer session will be webcast live and can be accessed by visiting the Investor homepage section of Enanta's website at [www.enanta.com](http://www.enanta.com). A replay of the presentation and question and answer session will be available following the sessions and will be archived for approximately 60 days.

### **About Enanta**

Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field. Enanta is discovering, and in some cases developing, novel inhibitors designed for use against the hepatitis C virus (HCV). These inhibitors include members of the direct acting antiviral (DAA) inhibitor classes – protease (partnered with AbbVie), NS5A (partnered with Novartis) and nucleotide polymerase – as well as a host-targeted antiviral (HTA) inhibitor class targeted against cyclophilin. Additionally, Enanta has created a new class of antibiotics, called Bicyclolides, for the treatment of multi-drug resistant bacteria, with a focus on developing an intravenous and oral treatment for hospital and community MRSA (methicillin-resistant *Staphylococcus aureus*) infections.

Source: Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc.  
Carol Miceli, 617-607-0710  
[cmiceli@enanta.com](mailto:cmiceli@enanta.com)